Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

NCT01121939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG: Bevacizumab
DRUG: Pertuzumab
DRUG: Sandostatin LAR® Depot

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]